Cargando…
MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the most common kind of pediatric cancer. Although the cure rates in ALL have significantly increased in developed countries, still 15–20% of patients relapse, with even higher rates in developing countries. The role of non-coding RNA genes as microRNAs (miRNAs)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049736/ https://www.ncbi.nlm.nih.gov/pubmed/36982511 http://dx.doi.org/10.3390/ijms24065436 |
_version_ | 1785014526090936320 |
---|---|
author | Mendiola-Soto, Diana Karen Bárcenas-López, Diego Alberto Pérez-Amado, Carlos Jhovani Cruz-Miranda, Gabriela Marisol Mejía-Aranguré, Juan Manuel Ramírez-Bello, Julian Hidalgo-Miranda, Alfredo Jiménez-Morales, Silvia |
author_facet | Mendiola-Soto, Diana Karen Bárcenas-López, Diego Alberto Pérez-Amado, Carlos Jhovani Cruz-Miranda, Gabriela Marisol Mejía-Aranguré, Juan Manuel Ramírez-Bello, Julian Hidalgo-Miranda, Alfredo Jiménez-Morales, Silvia |
author_sort | Mendiola-Soto, Diana Karen |
collection | PubMed |
description | Acute lymphoblastic leukemia (ALL) is the most common kind of pediatric cancer. Although the cure rates in ALL have significantly increased in developed countries, still 15–20% of patients relapse, with even higher rates in developing countries. The role of non-coding RNA genes as microRNAs (miRNAs) has gained interest from researchers in regard to improving our knowledge of the molecular mechanisms underlying ALL development, as well as identifying biomarkers with clinical relevance. Despite the wide heterogeneity reveled in miRNA studies in ALL, consistent findings give us confidence that miRNAs could be useful to discriminate between leukemia linages, immunophenotypes, molecular groups, high-risk-for-relapse groups, and poor/good responders to chemotherapy. For instance, miR-125b has been associated with prognosis and chemoresistance in ALL, miR-21 has an oncogenic role in lymphoid malignancies, and the miR-181 family can act either as a oncomiR or tumor suppressor in several hematological malignancies. However, few of these studies have explored the molecular interplay between miRNAs and their targeted genes. This review aims to state the different ways in which miRNAs could be involved in ALL and their clinical implications. |
format | Online Article Text |
id | pubmed-10049736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100497362023-03-29 MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia Mendiola-Soto, Diana Karen Bárcenas-López, Diego Alberto Pérez-Amado, Carlos Jhovani Cruz-Miranda, Gabriela Marisol Mejía-Aranguré, Juan Manuel Ramírez-Bello, Julian Hidalgo-Miranda, Alfredo Jiménez-Morales, Silvia Int J Mol Sci Review Acute lymphoblastic leukemia (ALL) is the most common kind of pediatric cancer. Although the cure rates in ALL have significantly increased in developed countries, still 15–20% of patients relapse, with even higher rates in developing countries. The role of non-coding RNA genes as microRNAs (miRNAs) has gained interest from researchers in regard to improving our knowledge of the molecular mechanisms underlying ALL development, as well as identifying biomarkers with clinical relevance. Despite the wide heterogeneity reveled in miRNA studies in ALL, consistent findings give us confidence that miRNAs could be useful to discriminate between leukemia linages, immunophenotypes, molecular groups, high-risk-for-relapse groups, and poor/good responders to chemotherapy. For instance, miR-125b has been associated with prognosis and chemoresistance in ALL, miR-21 has an oncogenic role in lymphoid malignancies, and the miR-181 family can act either as a oncomiR or tumor suppressor in several hematological malignancies. However, few of these studies have explored the molecular interplay between miRNAs and their targeted genes. This review aims to state the different ways in which miRNAs could be involved in ALL and their clinical implications. MDPI 2023-03-12 /pmc/articles/PMC10049736/ /pubmed/36982511 http://dx.doi.org/10.3390/ijms24065436 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mendiola-Soto, Diana Karen Bárcenas-López, Diego Alberto Pérez-Amado, Carlos Jhovani Cruz-Miranda, Gabriela Marisol Mejía-Aranguré, Juan Manuel Ramírez-Bello, Julian Hidalgo-Miranda, Alfredo Jiménez-Morales, Silvia MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia |
title | MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia |
title_full | MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia |
title_fullStr | MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia |
title_full_unstemmed | MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia |
title_short | MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia |
title_sort | mirnas in hematopoiesis and acute lymphoblastic leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049736/ https://www.ncbi.nlm.nih.gov/pubmed/36982511 http://dx.doi.org/10.3390/ijms24065436 |
work_keys_str_mv | AT mendiolasotodianakaren mirnasinhematopoiesisandacutelymphoblasticleukemia AT barcenaslopezdiegoalberto mirnasinhematopoiesisandacutelymphoblasticleukemia AT perezamadocarlosjhovani mirnasinhematopoiesisandacutelymphoblasticleukemia AT cruzmirandagabrielamarisol mirnasinhematopoiesisandacutelymphoblasticleukemia AT mejiaarangurejuanmanuel mirnasinhematopoiesisandacutelymphoblasticleukemia AT ramirezbellojulian mirnasinhematopoiesisandacutelymphoblasticleukemia AT hidalgomirandaalfredo mirnasinhematopoiesisandacutelymphoblasticleukemia AT jimenezmoralessilvia mirnasinhematopoiesisandacutelymphoblasticleukemia |